Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Lärkberget

2,41 SEK

+2,99 %

Mindre end 1K følgere

LARK

First North Stockholm

Investment

Financials

Oversigt
Finansielt overblik og estimater
Ejerskab
Sammenligne
+2,99 %
-0,41 %
-3,21 %
-1,63 %
+1,26 %
+2,99 %
-73,16 %
-84,22 %
-97,49 %

Lärkberget is a Swedish investment company. The company's main areas of activity are direct investments in low-risk instruments, investments in listed shares, funds and other liquid asset classes, as well as participation in bridge loans and guarantee commitments, investments in unlisted profitable companies, and reverse acquisitions. Lärkberget is headquartered in Stockholm.

Læs mere
Markedsværdi
47,72 mio. SEK
Aktieomsætning
104,63 t SEK
Omsætning
330 t
EBIT %
-14.309,09 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
12.2
2026

Årsrapport '25

7.5
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Eksterne analyser14.2.2025, 10.01

CombiGene: Making place for new ventures - VH Corp

• All research activities discontinued • Notice of an extraordinary general meeting on February 20, 2025 • Q&A with chairman Luca Di Stefano After a strategic evaluation of its operations, CombiGene’s board decided to discontinue all research activities...

Lärkberget
Pressemeddelelse14.2.2025, 08.21

Västra Hamnen Market Focus: CombiGene: Making place for new ventures

Lärkberget
Selskabsmeddelelse14.2.2025, 07.50

Year-end report January-December 2024 CombiGene AB (Publ)

Lärkberget

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse28.1.2025, 07.30

Discontinuation of research activities

Lärkberget
Selskabsmeddelelse9.1.2025, 15.00

Stockslätten AB acquires all shares from Strategic Partners A/S

Lärkberget
Selskabsmeddelelse9.1.2025, 14.50

Clarification regarding the management's role during the restructuring period

Lärkberget
Selskabsmeddelelse9.1.2025, 07.45

CombiGene initiates restructuring as part of strategic review to maximize shareholder value

Lärkberget
Selskabsmeddelelse17.12.2024, 13.30

CombiGene AB (publ): Nominating committee

Lärkberget
Selskabsmeddelelse10.12.2024, 13.50

Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

Lärkberget
Pressemeddelelse2.12.2024, 14.00

CombiGene conducts Extraordinary General Meeting

Lärkberget
Selskabsmeddelelse14.11.2024, 14.40

Shareholders’ proposal for election of Board of Directors

Lärkberget
Eksterne analyser11.11.2024, 13.39

CombiGene: Strategic consequences after CG01 - VH Corp

* Implementing cost savings and new priorities * New propositions from the main shareholder * Our revised fair value estimate is SEK 8.27 (12.19) per share In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again...

Lärkberget
Selskabsmeddelelse8.11.2024, 08.00

Interim report January – September 2024 for CombiGene AB (publ)

Lärkberget
Selskabsmeddelelse1.11.2024, 09.00

NOTICE OF EXTRAORDINARY GENERAL MEETING IN COMBIGENE AB (PUBL)

Lärkberget
Selskabsmeddelelse31.10.2024, 17.00

The Board of Directors of CombiGene has received proposals from the Company’s largest shareholder for the Extraordinary General Meeting intended to be convened

Lärkberget
Pressemeddelelse30.10.2024, 08.07

BioStock: CombiGene implements cost savings

Lärkberget
Eksterne analyser30.10.2024, 06.21

CombiGene: New priorities after strategic decision - VH Corp

* Terminating the CG01 programme * Implementing cost savings to prolong the financial runway * Our fair value estimate is under review Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway...

Lärkberget
Pressemeddelelse29.10.2024, 15.15

Västra Hamnen Market Focus: CombiGene: New priorities after strategic decision

Lärkberget
Selskabsmeddelelse28.10.2024, 07.50

CombiGene Initiates Measures to Extend Liquidity Horizon by Sharpening Strategic Focus on Gene Therapy, Prioritizing Pipeline Assets, and Implementing a Cost Reduction Program

Lärkberget
Selskabsmeddelelse30.9.2024, 11.15

CombiGene announces new preclinical research results in the epilepsy project

Lärkberget
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.